Clinical trial
A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Assess the Efficacy and Safety of Clazosentan in Preventing Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI), in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH)
NCT03585270 is registered in ClinicalTrials.gov with Idorsia Pharmaceuticals Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Assess the Efficacy and Safety of Clazosentan in Preventing Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI), in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH)
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 3, 2019
- Completion date
- November 18, 2022
- Enrollment
- 409 (actual)
- Sites
- 80
Conditions
As the registry lists them; a condition with its own page is linked.
aneurysmal subarachnoid hemorrhage